Joseph Shulman - 12 Feb 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Joseph Shulman
Issuer symbol
RYTM
Transactions as of
12 Feb 2025
Transactions value $
-$26,452
Form type
4
Date filed
14 Feb 2025, 16:57
Previous filing
11 Feb 2025
Next filing
19 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Sale -$26.1K -462 -7.6% $56.39 5.62K 12 Feb 2025 Direct F1
transaction RYTM Common Stock Sale -$400 -7 -0.12% $57.09 5.61K 12 Feb 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.